As previously reported (42), we observed mutations in TP53 and CTNNB1 in 27 patients with ovarian endometrioid carcinomas (68% of patients) and four patients with uterine endometrioid carcinomas (36% of patients). Here, TP53 is linked to endometrial endometrioid adenocarcinoma.